Fibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry Conference

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, will present at the Alliance for Regenerative Medicine’s (ARM) 2nd Annual Regen Med Investor Day at 4:00 p.m. EDT on Wednesday, March 26, 2014 at the Metropolitan Club in New York, and the BioCentury Future Leaders in the Biotech Industry conference at 10:30 a.m. EDT on Friday, March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York. Mr. Weaver will discuss the company’s autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.